NeoGenomics Joins Thermo Fisher Scientific’s Companion Diagnostic Center of Excellence Program with the Launch of Oncomine Dx Target Test
FORT MYERS, FL–(Marketwired – December 05, 2017) – NeoGenomics, Inc. (NASDAQ: NEO), a leading global specialty oncology testing laboratory, has signed an agreement with Thermo Fisher Scientific to join the Next-Generation Sequencing Companion Dx Center of Excellence Program (COEP). NeoGenomics is one of the first laboratories to offer the newly FDA-approved Oncomine Dx Target Test for Non-Small Cell Lung Cancer (NSCLC). This methodology allows rapid analysis of samples compared to previously approved testing approaches.
NeoGenomics’ Pharma Services Division supported the analytical validation of the Oncomine Dx Target Test for submission to the FDA. The test evaluates 23 genes associated with non-small cell lung cancer (NSCLC), and can be used to identify patients who may be eligible for treatment with one of the following: BRAF V600E for the combined therapy of dabrafenib and trametinib, ROS1 fusions for crizotinib, and L858R and Exon19 deletions for gefitinib. Effective immediately, physicians may now submit core needle biopsies or surgical resections of lung specimens or metastatic disease to NeoGenomics for testing to determine which targeted therapy in NSCLC is most suitable for an individual patient.
Douglas VanOort, Chairman and Chief Executive Officer of NeoGenomics, stated, “We are honored to have worked with Thermo Fisher during the product testing phase and to now commercialize the Oncomine Dx Target Test as one of the first laboratories to offer it nationwide. This approval and launch of Oncomine Dx for NSCLC is an excellent example of the continuum of service we provide – from research and development in our Pharma Services Division to immediate clinical testing in our Clinical Services Division. We are now providing pre-clinical R&D services and clinical trials support services for more than 300 discrete clinical trial projects requiring data on biomarkers.”
“We are pleased to have NeoGenomics as a member of Thermo Fisher’s Next-Generation Sequencing Companion Dx Center of Excellence Program,” said Joydeep Goswami, president of Clinical Next-Generation Sequencing and Oncology for Thermo Fisher Scientific. “They join a leading group of reference laboratories that strive to offer the most advanced solutions designed to help physicians make more informed decisions so their patients can get on the right therapies quickly.”
About NeoGenomics, Inc.
NeoGenomics, Inc. specializes in cancer genetics testing and information services. The Company provides one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company’s Pharma Services division serves pharmaceutical clients in clinical trials and drug development.
Headquartered in Fort Myers, FL, NeoGenomics operates CLIA-certified laboratories in Aliso Viejo and Fresno, California; Tampa and Fort Myers, Florida; Houston, Texas and Nashville, Tennessee. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, integrated service delivery networks, and managed care organizations throughout the United States. For additional information about NeoGenomics, visit www.neogenomics.com.
Except for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward-looking statements. These forward-looking statements involve a number of risks and uncertainties that could cause actual future results to differ materially from those anticipated in the forward-looking statements. Actual results could differ materially from such statements expressed or implied herein. Factors that might cause such a difference include, among others, the company’s ability to continue gaining new customers, offer new types of tests, and otherwise implement its business plan. As a result, this press release should be read in conjunction with the company’s periodic filings with the SEC.
For further information, please contact:
Steven C. Jones
Director of Investor Relations